Physician profile
Ashutosh Kacker
NPI 1336128362
$19,638.94
in general payments reported to CMS, 2019-2025
20 companies · $3,138 in 2025
The $3,138 reported for 2025 was more than what 94% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $1,306 · 2021: $510 · 2022: $2,465 · 2023: $8,413 · 2024: $3,623 · 2025: $3,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,242 · Honoraria: $4,548 · Consulting Fee: $4,480 · Travel and Lodging: $904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,241.56 |
| Honoraria | $4,548.02 |
| Consulting Fee | $4,480.00 |
| Travel and Lodging | $904.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $5,815.13 | 2019-2025 | |
| Horizon Therapeutics Plc | $4,449.43 | 2023 | Tepezza |
| Inspire Medical Systems, INC. | $2,282.77 | 2022-2025 | Inspire |
| Medtronic, INC. | $1,701.83 | 2022-2025 | Sinuva, Propel |
| Optinose US, INC. | $1,500.00 | 2022 | |
| Aerin Medical INC. | $1,418.26 | 2020-2023 | |
| Neurent Medical Limited | $623.26 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark System, Neuromark Device |
| Stryker Corporation | $463.28 | 2022-2025 | Scopis Ent, Nasopore, Xpress Loprofile |
| Intersect Ent, INC. | $308.05 | 2021 | |
| Integra Lifesciences Corporation | $276.77 | 2024-2025 | Acclarent Aera, Trudi Probe, Relieva Spinplus Nav |
| 3-D Matrix, INC. | $182.93 | 2025 | |
| Carl Zeiss Meditec USA, INC. | $148.02 | 2023 | Kinevo 900 |
| Acclarent, INC | $143.07 | 2019-2023 | Trudi Nav Cable |
| Spirair, INC. | $113.87 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $79.57 | 2023 | Airsupra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $45.34 | 2025 | Remede System |
| Regeneron Healthcare Solutions, INC. | $45.34 | 2022-2023 | Dupixent |
| Glaxosmithkline, LLC. | $22.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.19 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashutosh Kacker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.